The Sunshine Act: What it means to you, what you need to do

Article

The Physician Payments Sunshine Act requires manufacturers of drugs, medical devices, and biologicals that participate in U.S. federal healthcare programs to report certain payments and items of value given to members of the health care community.

 

Washington-Before the fiscal year goes any farther, this may be a good time to review the newly implemented Physician Payments Sunshine Act, better known simply as the Sunshine Act, which went into effect August 1.

The Sunshine Act is meant to enhance transparency in relationships between the pharmaceutical and drug manufacturing industry and doctors or teaching hospitals. The act requires manufacturers of drugs, medical devices, and biologicals that participate in U.S. federal healthcare programs to report certain payments and items of value given to members of the health care community.

Manufacturers are required to collect and track payment, transfer, and ownership information. The compiled data is then submitted to the Centers for Medicare & Medicaid Services (CMS) on an annual basis. Also, manufacturers and group purchasing organizations must report certain ownership interests held by doctors and their immediate family members.

Most of the information contained in the reports will be available on a public, searchable Web site starting Q4 2014. Doctors have the right to review their reports and challenge data that are false, inaccurate, or misleading.

To help doctors and the medical community at large navigate this new reporting obligation, the AMA offers a Toolkit for Physician Financial Transparency Reports . The Toolkit is a guide to complying with the process before your 2013 financial data is published online next year.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
ODs reflect on their time in Minneapolis, Minnesota, citing continuing education, tech updates, and networking opportunities as valued takeaways from the meeting.
Nora Lee Cothran, OD, FAAO, discussed the importance of optometrists addressing mental health with patients in their chair.
Nora Lee Cothran, OD, FAAO, moderated an Innovation Hub panel that featured 3 companies, giving insights into what's to come in the optometric industry.
Selina McGee, OD, shares what she wants to see in future State of Dry Eye surveys and how this year's results will affect her patient care.
Marc Bloomenstein, OD, FAAO, is a clinical investigator in the trials and overviews the transformative potential of LNZ100.
Shawn Hobbs, OD, previews the annual NOA convention, which takes place in Columbus, Ohio, from July 10 to 12, 2025.
Clark Chang, OD, MSA, MSc, FAAO, gave a presentation alongside Susan Gromacki, OD, MS, FAAO, FSLS, at this year's Optometry's Meeting.
Selina McGee, OD, FAAO, Dipl ABO, shares key takeaways and a personal anecdote relating to the State of Dry Eye survey results.
Devin Sasser, OD, shares his excitement for Acuvue Oasys MAX 1-Day multifocal for astigmatism, the first and only daily disposable multifocal toric contact lens.
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO.
© 2025 MJH Life Sciences

All rights reserved.